These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 17459487)
61. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison. Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542 [TBL] [Abstract][Full Text] [Related]
62. Attenuated and delayed niacin skin flushing in schizophrenia and affective disorders: A potential clinical auxiliary diagnostic marker. Wang DD; Hu XW; Jiang J; Sun LY; Qing Y; Yang XH; Gao Y; Cui GP; Li MH; Wang PK; Zhang J; Zhuang Y; Li ZZ; Li J; Guan LL; Zhang TH; Wang JJ; Ji F; Wan CL Schizophr Res; 2021 Apr; 230():53-60. PubMed ID: 33677199 [TBL] [Abstract][Full Text] [Related]
63. Measurement of insight in patients with bipolar disorder: are self-rated scales developed for patients with schizophrenia applicable? Jónsdóttir H; Engh JA; Friis S; Birkenaes A; Ringen PA; Vaskinn A; Sundet K; Opjordsmoen S; Andreassen OA J Nerv Ment Dis; 2008 Apr; 196(4):333-5. PubMed ID: 18414129 [TBL] [Abstract][Full Text] [Related]
64. No evidence for physical anhedonia as a candidate symptom or an endophenotype in bipolar affective disorder. Etain B; Roy I; Henry C; Rousseva A; Schürhoff F; Leboyer M; Bellivier F Bipolar Disord; 2007 Nov; 9(7):706-12. PubMed ID: 17988360 [TBL] [Abstract][Full Text] [Related]
65. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia. Kunz M; Gama CS; Andreazza AC; Salvador M; Ceresér KM; Gomes FA; Belmonte-de-Abreu PS; Berk M; Kapczinski F Prog Neuropsychopharmacol Biol Psychiatry; 2008 Oct; 32(7):1677-81. PubMed ID: 18657586 [TBL] [Abstract][Full Text] [Related]
66. Nicotine effects on mismatch negativity in nonsmoking schizophrenic patients. Inami R; Kirino E; Inoue R; Suzuki T; Arai H Neuropsychobiology; 2007; 56(2-3):64-72. PubMed ID: 18037816 [TBL] [Abstract][Full Text] [Related]
67. SKINREMS-A New Method for Assessment of the Niacin Skin Flush Test Response in Schizophrenia. Karakula-Juchnowicz H; Rog J; Wolszczak P; Jonak K; Stelmach E; Krukow P J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32545806 [TBL] [Abstract][Full Text] [Related]
68. Is 'bipolar disorder' the brain's autopoietic response to schizophrenia? Llewellyn S Med Hypotheses; 2009 Oct; 73(4):580-4. PubMed ID: 19589644 [TBL] [Abstract][Full Text] [Related]
69. Sexual problems in a sample of the Turkish psychiatric population. Hariri AG; Karadag F; Gurol DT; Aksoy UM; Tezcan AE Compr Psychiatry; 2009; 50(4):353-60. PubMed ID: 19486734 [TBL] [Abstract][Full Text] [Related]
70. Cardiovascular disease and metabolic risk factors in male patients with schizophrenia, schizoaffective disorder, and bipolar disorder. Kilbourne AM; Brar JS; Drayer RA; Xu X; Post EP Psychosomatics; 2007; 48(5):412-7. PubMed ID: 17878500 [TBL] [Abstract][Full Text] [Related]
71. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Maccubbin D; Koren MJ; Davidson M; Gavish D; Pasternak RC; Macdonell G; Mallick M; Sisk CM; Paolini JF; Mitchel Y Am J Cardiol; 2009 Jul; 104(1):74-81. PubMed ID: 19576324 [TBL] [Abstract][Full Text] [Related]
72. Potential use of the topical niacin skin test in early psychosis -- a combined approach using optical reflection spectroscopy and a descriptive rating scale. Smesny S; Berger G; Rosburg T; Riemann S; Riehemann S; McGorry P; Sauer H J Psychiatr Res; 2003; 37(3):237-47. PubMed ID: 12650743 [TBL] [Abstract][Full Text] [Related]
73. Retrospective parent report of psychiatric histories: do checklists reveal specific prodromal indicators for postpubertal-onset pediatric bipolar disorder? Rucklidge JJ Bipolar Disord; 2008 Feb; 10(1):56-66. PubMed ID: 18199242 [TBL] [Abstract][Full Text] [Related]
74. A potential objective marker in first-episode schizophrenia based on abnormal niacin response. Hu Y; Xu L; Gan R; Wu G; Tang X; Wei Y; Cui H; Hui L; Tang Y; Li C; Chen T; Wan C; Wang J; Zhang T Schizophr Res; 2022 May; 243():405-412. PubMed ID: 34187733 [TBL] [Abstract][Full Text] [Related]
75. The P300 as a possible endophenotype for schizophrenia and bipolar disorder: Evidence from twin and patient studies. Bestelmeyer PE; Phillips LH; Crombie C; Benson P; St Clair D Psychiatry Res; 2009 Oct; 169(3):212-9. PubMed ID: 19748132 [TBL] [Abstract][Full Text] [Related]
76. Attention network test (ANT) reveals gender-specific alterations of executive function in schizophrenia. Urbanek C; Neuhaus AH; Opgen-Rhein C; Strathmann S; Wieseke N; Schaub R; Hahn E; Dettling M Psychiatry Res; 2009 Jul; 168(2):102-9. PubMed ID: 19464736 [TBL] [Abstract][Full Text] [Related]
77. A systems approach to prefrontal-limbic dysregulation in schizophrenia. Rădulescu AR; Mujica-Parodi LR Neuropsychobiology; 2008; 57(4):206-16. PubMed ID: 18756092 [TBL] [Abstract][Full Text] [Related]
78. Understanding why patients with schizophrenia do not perceive the hollow-mask illusion using dynamic causal modelling. Dima D; Roiser JP; Dietrich DE; Bonnemann C; Lanfermann H; Emrich HM; Dillo W Neuroimage; 2009 Jul; 46(4):1180-6. PubMed ID: 19327402 [TBL] [Abstract][Full Text] [Related]